僅用于工業應用或科學研究，不可用于人類或動物的臨床診斷或治療，非藥用. Modotuximab （Anti-Human EGFR Recombinant Antibody） is an IgG1κ-type chimeric antibody targeting human EGFR protein. Modotuximab contains a portion of Futuximab that binds to two independent, non-overlapping epitopes on EGFR. Modotuximab promotes cross-linking of EGFR on the cell surface and promotes EGFR cellular internalization and degradation. Modotuximab has antitumor activity in vivo